Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research focused on Chronic lymphocytic leukemia and Fludarabine, with related work in Alemtuzumab, Rituximab, Chlorambucil. Notable publications include 'Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions', 'Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial', and 'High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations'.
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial
High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations
Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial
Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW